Want to see GRTXD full AI Analyst Report?
Top Page
Galera Therapeutics
(OTC:GRTXD)
Select Model
Select Model
Rating:46Neutral
Price Target:
$16.00
▲(79900.00% Upside)
Action:Reiterated
Date:07/15/26
Overall score is held down primarily by weak fundamentals (no revenue, ongoing operating losses, and continued cash burn despite improved EBIT) and bearish-to-soft technicals (below key moving averages with negative MACD). Balance-sheet repair (zero debt, positive equity) and constructive corporate actions provide partial support, but valuation signals are hard to trust given the non-operating nature of recent reported profits.
Positive Factors
Balance-sheet repair
Elimination of debt and a return to positive equity materially reduce solvency risk and interest burden. For a clinical-stage biotech, having a cleaner balance sheet improves ability to negotiate partnerships, access capital on better terms, and survive extended clinical timelines without immediate refinancing pressure.
Negative Factors
Pre-revenue business model
With no product revenue, the company’s long-term viability depends on successful clinical development, licensing, or partner commercialization. That structural dependency elevates binary clinical and regulatory risk and makes cash runway and external financing the primary determinants of execution over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet repair
Elimination of debt and a return to positive equity materially reduce solvency risk and interest burden. For a clinical-stage biotech, having a cleaner balance sheet improves ability to negotiate partnerships, access capital on better terms, and survive extended clinical timelines without immediate refinancing pressure.
Read all positive factors
Galera Therapeutics (GRTXD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.00M
Dividend YieldN/A
Average Volume (3M)63.57K
Price to Earnings (P/E)<0.1
Beta (1Y)2.01
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,040,118
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Galera Therapeutics Business Overview & Revenue Model
Company Description
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC...
How the Company Makes Money
null...
Galera Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Galera Therapeutics Technical Analysis
Negative
0.02
Price Trends
18.72
Negative
15.12
Positive
9.80
Positive
Market Momentum
-0.40
Positive
41.04
Neutral
40.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTXD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 17.50, below the 50-day MA of 18.72, and below the 200-day MA of 9.80, indicating a neutral trend. The MACD of -0.40 indicates Positive momentum. The RSI at 41.04 is Neutral, neither overbought nor oversold. The STOCH value of 40.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRTXD.
Galera Therapeutics Risk Analysis
Galera Therapeutics disclosed 47 risk factors in its most recent earnings report. Galera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galera Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $25.27M | -1.99 | -77.79% | ― | 127.03% | 87.33% | |
46 Neutral | $19.00M | 0.05 | -210.64% | ― | ― | ― | |
42 Neutral | $955.50K | ― | ― | ― | -1.80% | -198.00% | |
| ― | $3.13M | -0.09 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
GRTXD
Galera Therapeutics
16.70
10.72
179.26%
QCLS
Q/C Technologies
3.48
-7.42
-68.07%
SCNI
Scinai Immunotherapeutics
0.26
-1.90
-87.82%
EVAX
Evaxion Biotech
3.05
0.43
16.41%
ONCO
Onconetix
0.77
-174.73
-99.56%
Galera Therapeutics Corporate Events
Other
Galera Therapeutics Announces Material Changes to Security Holder Rights
Neutral
Jul 13, 2026
Galera Therapeutics released only a fragmentary statement, providing no substantive information about its operations, products, services or strategic focus. The text does not describe the company’s industry, markets or any details that would...
Stock Split
Galera Therapeutics Announces Major Reverse Stock Split
Neutral
Jul 7, 2026
On July 7, 2026, Galera Therapeutics announced that its board approved a one‑for‑two hundred reverse stock split of its common stock, effective at 11:59 p.m. Eastern Time on July 12, 2026, with split‑adjusted trading to begin on ...
Business Operations and StrategyRegulatory Filings and Compliance
Galera Therapeutics Eliminates Series B Preferred, Simplifies Equity
Positive
May 19, 2026
On May 15, 2026, Galera Therapeutics, Inc. converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,839,103 shares of common stock in accordance with its governing certificate of designation. The company ...
Business Operations and StrategyShareholder Meetings
Galera Therapeutics Expands Share Authorization, Enhances Stockholder Rights
Neutral
May 15, 2026
On May 11, 2026, Galera Therapeutics doubled its authorized common stock from 200 million to 400 million shares through a charter amendment approved by stockholders at the company’s May 8, 2026 annual meeting. This move significantly expands...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Galera Shareholders Approve Governance Changes and Share Increase
Positive
May 11, 2026
At its combined 2025 and 2026 Annual Meeting of Stockholders held on May 8, 2026, Galera Therapeutics’ shareholders elected one Class III director to serve until the 2028 annual meeting and two Class I directors to serve until the 2029 annua...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.